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lar carcinomas who underwent liver transplantation was
26 months (range, 9 to 54). Among these patients, two re-
quired retransplantation because of recurrent viral hepa-
titis (one with HBV and one with HCV). Three patients
died perioperatively (6 percent). Altogether, eight patients
died after transplantation (17 percent), with recurrent
cancer accounting for only two of the deaths (Table 2).
Four patients had recurrent cancer a median of 3 months
after transplantation; two of them died, and a third pa-
tient with metastases to the lung was still alive 26 months
after transplantation. The fourth patient had a single sub-
cutaneous mass of hepatocellular carcinoma detected
along the needle track of the percutaneous liver biopsy
performed before transplantation; that tumor was sur-
gically removed, and the patient was free of disease 14
months later. In three of the four patients with recurrent
cancer, the tumor stage assigned preoperatively was low-
er than that of the resected tumor (two patients had more
than three tumors, and one patient’s tumor was more
than 5 cm in diameter). The fourth patient (who had the
subcutaneous recurrence) had a single tumor 2.8 cm in
diameter. The overall actuarial four-year survival was 75
percent, and the recurrence-free survival at four years
was 83 percent, with three-year standard errors of 5.8
percent and 5.9 percent, respectively (Fig. 1). After three
years, recurrence-free survival became higher than over-
all survival, because recurrence of cancer was excluded
at autopsy in some patients who died or because data
were censored earlier in the calculation of recurrence-
free survival.
The influence of several variables on overall and re-
currence-free survival is shown in Table 3. Survival was
not affected by the patient’s age or sex or by common
markers of chronic liver disease, such as the type of hep-
atitis virus and the Child–Pugh stage at the time of
transplantation. Of particular importance was the fact
that, as long as all liver cancers were removed at an
early stage, even classic prognostic factors such as the
T stage, number of tumors, serum alpha-fetoprotein con-
centration, and presence or absence of a capsule were
not statistically significant predictors of survival (with
so few recurrences, however, these analyses had very
low power).
In this selected group of patients with small tumors,
preoperative chemoembolization proved ineffective (Fig.
2), even though this treatment was not randomly as-
signed but, rather, was used only if liver function was
not seriously impaired. In the 28 pretreated patients
(58 percent of the total) four-year survival was 79 per-
cent and recurrence-free survival was 87 percent. Sim-
ilarly, 69 percent of the 20 patients who received no
treatment before transplantation were alive and 78 per-
cent were free of recurrence after the same period of
follow-up.
The selection of patients (and tumors) was the main
factor affecting survival after transplantation, as was
confirmed by the small number of recurrences (in four
patients) and by pathological examination of the ex-
planted livers, which revealed a median of 2 tumor mass-
es per liver (range, 1 to 11) and a median diameter of 1.5
cm per tumor (range, 0.2 to 6). With respect to TNM
stage, neither vascular invasion nor lymph-node metas-
tases were detected, and the number and size of the tu-
mors in each liver were not significantly different at var-
ious T stages. Fifteen patients had single tumors of 2 cm
or less in diameter (stage T1); 18 patients had a median
of 1 tumor 2 cm or less in diameter (stage T2); and 13
patients had multiple tumors (range, 2 to 10) 2.2 cm in
diameter (stage T3). Finally, only two patients had mul-
tiple tumors (range, 2 to 10) that were 2.5 cm or more
in diameter diffused to both lobes of the liver (stage T4).
The size, number, and location of tumors were the only
 
Figure 1. Overall Survival (Panel A) and Recurrence-free Sur-
vival (Panel B) after Liver Transplantation in 48 Patients with
Small Hepatocellular Carcinomas and Cirrhosis.
Data on the three patients who died within one month after trans-
plantation were included in the calculation of recurrence-free sur-
vival. The three-year standard errors are 5.8 percent for overall
survival and 5.9 percent for recurrence-free survival; 95 percent
confidence intervals (bars) are shown at one-year intervals.
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id-organ transplantation.
 
31
 
 Most of our patients were
treated with a cyclosporine-based immunosuppressive
regimen, with corticosteroids discontinued after six months
in most cases. The risk of recurrence among patients
who continue to receive corticosteroids may be as much
as four times higher than the risk in patients in whom
the corticosteroid is discontinued soon after transplanta-
tion.
 
32
 
 Our results confirm previous experience
 
2
 
 and may
lead to further studies of the influence of different im-
munosuppressive regimens on the development of can-
cer after transplantation, with particular reference to the
corticosteroid-sparing properties of tacrolimus and the
possible reduction in the dosage of immunosuppressive
agents under favorable conditions.
 
33
 
In the past, it was tempting to conclude that liver trans-
plantation for hepatocellular carcinoma was futile.
 
5,24
 
However, as documented in this study, long-term surviv-
al can be achieved with liver transplantation in careful-
ly selected patients.
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help and support at various stages of our work: D. Baratti, G. Cozzi,
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M. Barbi, M.L. Ribero, and A. Tagger at the Institute of Virology,
University of Milan, Milan; A. Alberti, L.S. Belli, and G. Ideo at Ni-
guarda Hospital, Milan; L. Caccamo, M. Colledan, L.R. Fassati,
D. Galmarini, and M. Langer at the Liver Transplant Unit, Maggiore
Hospital, Milan; M. Colombo at the Department of Internal Medi-
cine, University of Milan; R. Gesu, A. Lazzarin, L. Luzi, and C. Socci
at the Departments of Infectious Diseases, Internal Medicine, and
Surgery, San Raffaele Hospital, Milan; L. Pagliaro and U. Palazzo at
Cervello Hospital, Palermo, Italy; G. Corbetta and E. Grossi at San-
doz, Milan; A. Consonni at Fujisawa, Milan; and M.A. Cerri, A. Di
Padova, and P. Giulidori at Knoll, Milan. We are also indebted to
B. Ringe of Georg-August University, Göttingen, Germany, and to
D.H. Van Thiel, Oklahoma City, for helpful discussion of the results
of our study.
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Figure 3. Correlation of Post-Transplantation Pathological Con-
firmation of Early-Stage Hepatocellular Carcinoma with Overall
Survival (Panel A) and Recurrence-free Survival (Panel B)
among 48 Patients with Cirrhosis.
Data on the three patients who died within one month after trans-
plantation were included in the calculation of recurrence-free
survival. Before transplantation, all the patients were estimated
to have either a single hepatocellular carcinoma 
 
!
 
5 cm in diam-
eter or no more than three tumors each of which was 
 
!
 
3 cm in
diameter. After transplantation, the explanted livers were exam-
ined pathologically, and the patients whose tumors actually met
the predefined criteria were compared with those whose tumors
did not meet those criteria. Ninety-five percent confidence inter-
vals (bars) are shown at one-year intervals.
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  out	  HCC	  criteria	  
•  UCSF:	  1	  nodule	  ≤	  6.5	  cm,	  ≤	  3	  nodules	  (largest	  4.5	  
cm	  &	  total	  	  ≤	  !	  8	  cm	  
•  up-­‐to-­‐7:	  ≤	  7	  nodules,	  largest	  	  ≤	  7	  cm	  
•  Tokyo:	  5-­‐5	  rule:	  ≤	  5	  nodules,	  largest	  	  ≤	  5	  cm	  
•  Hangzou:	  total	  ≤	  !	  8	  cm	  or	  >	  !	  8	  cm	  	  with	  AFP	  <	  
400ng/ml	  
•  Asan	  (South	  Korea):	  ≤	  5	  cm,	  ≤	  6	  nodules	  
•  Shangai:	  1	  nodule	  ≤	  9	  cm,	  ≤	  3nodules	  (largest	  5	  
cm	  &	  total	  	  ≤	  !	  9	  cm	  

AFP	  model	  
recurrence. On the basis of the AUROC analysis, the best
cut-off value of the Cox score to stratify between low and
high risk of 5-year recurrence was 0.7 (AUROC, 0.701; 95%
confidence interval [CI], 0.63–0.76; sensitivity, 53.4%;
specificity, 81.6%; accuracy, 75.8%). Five-year recurrence
and 5-year overall survival rates statistically differed be-
tween patients at low (scores, !0.7) and high (scores,
!0.7) risk of recurrence, as shown in Figure 2A.
Three combinations of independent predictors defined
low-risk patients, as follows: (1) 1–3 nodules, maximum
diameter of the largest tumor of less than 3 cm, and log10
AFP !3 (or AFP !1000); (2) 1–3 nodules, maximum
diameter of the largest tumor of 3–6 cm, and log10 AFP
!2 (or AFP !100); and (3) more than 4 nodules, maxi-
mum diameter of the largest tumor of less than 3 cm, and
log10 AFP !2 (or AFP !100) (Table 1). Importantly, some
low-risk patients by the AFP model exceeded Milan crite-
ria such as patients in categories 2 and 3, with a log10 AFP
!2 (or AFP !100).
High-risk patients mainly consisted of those patients
exceeding the Milan criteria, but patients within Milan
criteria with log10 AFP !3 (or AFP levels !1000 ng/mL)
were also classified as high-risk patients.
From this model, fit between expected and observed
probabilities of 5-year recurrence was measured by the
Hosmer Lemeshow C test at a P value of .78.
The Simplified Version of the Model
A simplified, user-friendly version of the AFP
model is presented in Table 2.
This simplified version was derived from the original
model by linear transformation of the " coefficients ("
coefficients " 3, rounded).
In addition, AFP values were expressed as absolute
values (log10 AFP [ng/mL] of 2 and 3 corresponding to
AFP values of 100 and 1000 ng/mL, respectively).
In this simplified version, the score was calculated by
adding the individual points for each obtained variable. A
cut-off value of 2 separated patients at high and low risk
of recurrence (low-risk patients had a score !2 and high-
risk patients had a score !2). The cut-off value of 2
selected exactly the same patients as the original Cox score
of 0.7 as a cut-off value and is used throughout this article
to differentiate between patients at high and low risk of
recurrence.
Validation of the AFP Model in the VCABM
Computation of individual Cox score values in the
VCABM supported the simplified cut-off value of 2 as a
threshold between patients at low and high risk of recur-
rence. Five-year recurrence rates were 8.8% # 1.7% vs
50.6% # 10.2% (P $ .001) among patients with scores of
!2 and !2, respectively (Figure 2B), and 5-year survival
rates of 67.8% # 3.4% and 47.5% # 8.1% (P % .002) were
Figure 2. Tumor recurrence
(red) and survival rates (black)
according to the AFP model in
the (A) training cohort and in the
(B) validation cohort ABM. Solid
line for low-risk group, dashed
line for high-risk group.
Table 2. Simplified, User-Friendly Version of the AFP Model
Variables " coefficient Hazard ratio Points
Largest diameter, cm
!3 0 1 0
3–6 0.272 1.31 1
!6 1.347 3.84 4
Number of nodules
1–3 0 1 0
#4 0.696 2.01 2
AFP level, ng/mL
!100 0 1 0
100–1000 0.668 1.95 2
!1000 0.945 2.57 3
NOTE. The score is calculated by adding the individual points for each
obtained variable. A cut-off value of 2 separates between patients at
high and low risk of recurrence. In this simplified version, a cut-off
value of 2 selected exactly the same patients as the original Cox score
cut-off value of 0.7.
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This article has an accompanying continuing medical education activity on page e14. Learning Objective: Upon completion
of this training, successful learners will be educated that Milan criteria are too restrictive and will be able to identify liver
transplantation candidates for HCC beyond Milan criteria patients at low risk of recurrence and high survival rates.
BACKGROUND& AIMS: The aim of this study was to
generate an improved prognostic model for predicting re-
currence in liver transplant candidates with hepatocellular
carcinoma (HCC). METHODS: Predictors of recurrence
were tested by a Cox model analysis in a training cohort of
537 patients transplanted for HCC. A prognostic score was
developed and validated in a national cohort of 435 patients
followed up prospectively. RESULTS: !-Fetoprotein (AFP)
independently predicted tumor recurrence and correlated
with vascular invasion and differentiation. At a Cox score
threshold of 0.7 (area under the receiver operating charac-
teristic curve, 0.701; 95% confidence interval, 0.63–0.76; ac-
curacy, 75.8%), a model combining log10 AFP, tumor size,
and number was highly predictive of tumor recurrence and
death. By using a simplified version of the model, with
untransformed AFP values, a cut-off value of 2 was identi-
fied. In the validation cohort, a score greater than 2 predicted
a marked increase in 5-year risk of recurrence (50.6% !
10.2% vs 8.8% ! 1.7%; P " .001) and decreased survival
(47.5%! 8.1% vs 67.8%! 3.4%; P# .002) as compared with
others. Among patients exceeding Milan criteria, a score of 2
or lower identified a subgroup of patients with AFP levels
less than 100 ng/mL with a low 5-year risk of recurrence
(14.4%! 5.3% vs 47.6%! 11.1%; P# .006). Among patients
within Milan criteria, a score greater than 2 identified a
subgroup of patients with AFP levels greater than 1000
ng/mL at high risk of recurrence (37.1% ! 8.9% vs 13.3% !
2.0%; P " .001). Net reclassification improvement showed
that predictability of the AFP model was superior to Milan
criteria. CONCLUSIONS: Prediction of tumor recur-
rence is improved significantly by a model that incorpo-
rates AFP. We propose the adoption of new selection
criteria for HCC transplant candidates, taking into ac-
count AFP.
Keywords: Liver Transplantation; Hepatocellular Carci-
noma; AFP.
Liver transplantation (LT) is the best treatment for hepato-cellular carcinoma (HCC) at early stages because it removes
the tumor as well as the underlying cirrhotic liver. However, as
a result of organ shortage, guidelines have restricted transplan-
tation to HCC patients with an expected 5-year post-transplan-
tation survival of greater than 50%,1 and, in most programs, an
expected 5-year post-transplantation survival similar to
survival achieved after liver transplantation for benign
liver diseases (ie, 70%).
In this setting, the Milan criteria2 were adopted as a
prioritization tool by the United Network of Organ Sharing
and by the majority of transplant programs more than 10
years ago, and have been shown consistently to identify a
subgroup of patients with 5-year survival rates ranging from
65% to 80%, with an acceptable risk of tumor recurrence of
Abbreviations used in this paper: ABM, Agence de la Biomédecine;
AFP, !-fetoprotein; AUROC, area under the receiver operating charac-
teristic; CI, confidence interval; HCC, hepatocellular carcinoma; LT, liver
transplantation; NRI, net reclassification improvement; TC, training
cohort; VC, validation cohort.
© 2012 by the AGA Institute
0016-5085/$36.00
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5 yr Recurrence rate	  
IN	   10 % +- 2.5	  
OUT	   33 % +- 7	  
5 yr Recurrence rate	  
IN	   12% +- 2.5 
OUT	   39 % +- 9 
5 yr Recurrence rate	  
IN	   12% +- 2.5 
OUT	   44 % +- 11 
Be-­‐LIAC	  cohort	  
aFP model	  
IN	   OUT	  
Milan	  
IN	   167 (69 %)	   13 (5%)	  
OUT	   38 (16%)	   24 (10%)	  
Asan criteria 
IN OUT 
Milan 
IN 177 (74 %) 0 (0 %) 
OUT 36 (15 %) 26 (11 %) 
5 yr: 24 % +- 8 5 yr: 17 % +- 6 
Be-­‐LIAC	  cohort	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Abstract
AIM: To evaluate the prognostic value of pretreatment 
FDG positron emission tomography computed 
tomography (PET-CT) in patients with hepatocarcinoma 
treated by liver transplantation (LT). 
METHODS: The authors retrospectively analyzed 
the data of 27 patients (mean age 58 ± 9 years) who 
underwent FDG PET-CT before LT for hepatocarcinoma. 
Mean follow-up was 26 ± 18 mo. The FDG PET/CT was 
performed according to a standard clinical protocol: 
4 MBqFDG/kg body weight, uptake 60 min, low-dose 
non-enhanced CT. The authors measured the SUVmax 
and SUVmean of the tumor and the normal liver. The 
tumor/liver activity ratios (RSUVmax and RSUVmean) 
were tested as prognostic factors and compared to 
the following conventional prognostic factors: MILAN, 
CLIP, OKUDA, TNM stage, alphafoetoprotein level, 
portal thrombosis, size of the largest nodule, tumor 
differentiation, microvascular invasion, underlying 
cirrhosis and liver function. 
RESULTS: Overall and recurrence free survivals were 
80.7% and 67.4% at 3 years, and 70.6% and 67.4% 
at 5 years, respectively. According to a multivariate 
Cox model, only FDG PET/CT RSUVmax predicted 
recurrence free survival. Even though the MILAN 
criteria alone were not predictive, it is worth noting that 
none of the patients outside the MILAN criteria and 
with RSUVmax < 1.15 relapsed. 
CONCLUSION: FDG PET/CT with an RSUVmax cut-
off value of 1.15 is a strong prognostic factor for 
recurrence and death in patients with HCC treated 
by LT in this retrospective series. Further prospective 
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Pa?ents	  
•  52	  LT	  for	  HCC	  during	  the	  study	  period	  
•  27	  fulﬁlled	  the	  inclusion	  criteria	  
	  -­‐	  13	  Milan	  in	  (SE)	  
	  -­‐	  14	  Milan	  out	  (rescue	  alloca?on	  &	  DCD)	  
	  
•  Mean	  follow-­‐up:	  26	  months	  
•  Mean	  interval	  between	  PET	  &	  LT:	  4	  months	  
	  	  
Original article
Donor age as a risk factor in donation after circulatory death
liver transplantation in a controlled withdrawal protocol
programme
O. Detry1, A. Deroover1, N. Meurisse1, M. F. Hans1, J. Delwaide2, S. Lauwick3, A. Kaba3, J. Joris3,
M. Meurisse1 and P. Honore´1
Departments of 1Abdominal Surgery and Transplantation, 2Hepato-Gastroenterology and 3Anaesthesiology and Intensive Care, Centre Hospitalier
Universitaire de Lie`ge, University of Lie`ge, Lie`ge, Belgium
Correspondence to: Professor O. Detry, Department of Abdominal Surgery and Transplantation, CHU Lie`ge, Sart Tilman B35, B4000 Lie`ge, Belgium
(e-mail: olivier.detry@transplantation.be)
Background: Results of donation after circulatory death (DCD) liver transplantation are impaired by
graft loss, resulting mainly from non-anastomotic biliary stricture. Donor age is a risk factor in deceased
donor liver transplantation, and particularly in DCD liver transplantation. At the authors’ institute, age
is not an absolute exclusion criterion for discarding DCD liver grafts, DCD donors receive comfort
therapy before withdrawal, and cold ischaemia is minimized.
Methods: All consecutive DCD liver transplantations performed from 2003 to 2012 were studied
retrospectively. Three age groups were compared in terms of donor and recipient demographics,
procurement and transplantation conditions, peak laboratory values during the first post-transplant 72h,
and results at 1 and 3 years.
Results: A total of 70 DCD liver transplants were performed, including 32 liver grafts from donors
aged 55 years or less, 20 aged 56–69 years, and 18 aged 70 years or more. The overall graft survival
rate at 1month, 1 and 3 years was 99, 91 and 72 per cent respectively, with no graft lost secondary to
non-anastomotic stricture. No difference other than age was noted between the three groups for donor
or recipient characteristics, or procurement conditions. No primary non-function occurred, but one
patient needed retransplantation for artery thrombosis. Biliary complications were similar in the three
groups. Graft and patient survival rates were no different at 1 and 3 years between the three groups
(P=0·605).
Conclusion: Results for DCD liver transplantation from younger and older donors were similar. Donor
age above 50 years should not be a contraindication to DCD liver transplantation if other donor risk
factors (such as warm and cold ischaemia time) are minimized.
Presented to the European Society for Organ Transplantation (ESOT) 2013 Congress, Vienna, Austria,
September 2013
Paper accepted 5 February 2014
Published online 28 April 2014 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.9488
Introduction
Donation after circulatory death (DCD) has been proposed
as a means to increase the pool of hepatic grafts1. However,
compared with donation after brain death (DBD),
DCD imposes additional warm ischaemic injury before
organ preservation by cooling and flushing. The results
of multicentre series of DCD liver transplantation2–5
demonstrate a greater risk of graft failure as a result of
non-anastomotic stricture of the graft bile ducts.
Advanced donor age has been determined as a significant
prognostic factor in DBD liver transplantation6. Aged
livers have less regenerative capacity7 and are more
susceptible to ischaemia–reperfusion injury8 and hepatitis
C virus (HCV) reinfection after liver transplantation9,10.
Despite these facts, there is no absolute limit of donor
age for DBD liver transplantation11,12. In DCD liver
transplantation, donor age above 50 years has been
identified as an additional risk factor for graft loss in
multicentre series such as that of the United Network for
© 2014 BJS Society Ltd BJS 2014; 101: 784–792
Published by John Wiley & Sons Ltd
Pa?ent	  survival	  
•  One	  year	  survival:	  85%	  
•  Five-­‐year	  survival:	  70.6%	  
Recurrence-­‐free	  survival	  



Liver	  transplanta?on	  for	  HCC:	  	  
do	  size	  &	  number	  really	  maUer??	  
YES!	  
HCC	  
•  Number	  of	  nodules	  &	  size	  is	  not	  the	  magic	  
bullet	  
•  MILAN	  criteria	  are	  too	  restric?ve	  and	  should	  
be	  enlarged	  
•  Tumor	  biology	  &	  diﬀeren:a:on	  
	  -­‐	  AFP	  
	  -­‐	  Response	  to	  adjuvant	  therapy	  
	  -­‐	  PET	  scan	  ?	  
•  Post	  transplant	  chemotherapy	  ?	  
Project	  
•  Prospec?ve	  mul?centric	  na?onal	  evalua?on	  of	  
the	  prognos?c	  value	  of	  18FDG	  PET/CT	  in	  liver	  
transplanta?on	  for	  HCC	  
	  
– Primary	  inves?gator:	  	  ULg	  
– 6	  Belgian	  Centers:	  ULg,	  ULB,	  UCL,	  KUL,	  UZA,	  UZG	  


Role of Stromal Protein PRELP in The  
Hepatocellular Carcinoma  
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